CNSide Diagnostics, LLC became a wholly-owned subsidiary of Plus Therapeutics on July 31, 2025.
6 reports, 2 independent
Updated Jul 28
Gone quiet
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CNSide Diagnostics, LLC became a wholly-owned subsidiary of Plus Therapeutics on July 31, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Plus Therapeutics
biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswirePlus Therapeutics Provides US Launch Update for its CNSide® Diagnostic CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large priva
- GlobeNewswirePlus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases C
- GlobeNewswirePlus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO)
- Unknown outlet